New data presented at EHA 2026 showed durable long-term outcomes for BRUKINSA in patients aged 80 and older, while additional real-world analyses reinforced its competitive position in chronic lymphocytic leukemia.
Key Investor Takeaways
- BeOne Medicines (NASDAQ:ONC) presented long-term Phase 3 BRUKINSA data demonstrating durable efficacy in chronic lymphocytic leukemia (CLL) patients aged 80 and older.
- Nearly two-thirds of patients aged 80+ remained progression-free after six years of treatment, despite a high prevalence of adverse-risk disease features.
- Updated SEQUOIA results extended BRUKINSA’s long-term progression-free survival advantage over bendamustine-rituximab in first-line CLL.
- Real-world studies involving more than 250,000 patients showed favorable outcomes for BRUKINSA compared with other BTK inhibitors across multiple measures.
- The data strengthen BeOne’s effort to position BRUKINSA as the foundational BTK inhibitor in frontline CLL treatment.
Why ONC Stock Is In Focus
BeOne unveiled one of the largest datasets to date evaluating first-line BRUKINSA treatment in patients aged 80 years and older with chronic lymphocytic leukemia or small lymphocytic lymphoma. The analysis included 38 patients from the Phase 3 SEQUOIA study, many of whom carried high-risk genetic features such as TP53 mutations, del(17p), or unmutated IGHV.
After a median follow-up of nearly 79 months, BRUKINSA delivered a 100% overall response rate, with 63.8% progression-free survival and 75.9% overall survival at 72 months. More than one-third of patients remained on treatment at the time of analysis.
The company also reported updated 78-month SEQUOIA data showing progression-free survival of 71.8% for BRUKINSA compared with 31.0% for bendamustine-rituximab. Benefits were observed across both mutated and unmutated IGHV subgroups.
In parallel, BeOne presented several large real-world analyses showing lower risks of death, treatment discontinuation, and progression compared with competing BTK inhibitors, while also reporting lower one-year atrial fibrillation rates.
Why This Matters for Investors
The update is important because older patients represent a significant portion of the CLL population but have historically been underrepresented in pivotal clinical trials. The new data help address a key evidence gap by demonstrating long-term efficacy and tolerability in a group frequently encountered in routine clinical practice.
For investors, the findings may strengthen BRUKINSA’s competitive positioning within the BTK inhibitor market. Long-term efficacy data are particularly valuable in CLL, where treatment durations often extend for years and physicians prioritize durable disease control alongside safety and tolerability.
The real-world evidence presented alongside the clinical data may further support adoption by showing outcomes across broader patient populations outside the controlled environment of clinical trials. Lower reported rates of atrial fibrillation could also remain an important differentiator in older patients who frequently have cardiovascular comorbidities.
Additionally, patient-preference research presented by the company indicated that safety, effectiveness, and disease control are the factors most frequently influencing treatment decisions, while treatment duration itself was rarely cited. These findings may support BeOne’s focus on demonstrating durable efficacy and tolerability rather than emphasizing fixed treatment duration.
What To Watch Next
Investors will likely monitor:
- Additional long-term follow-up from the SEQUOIA trial.
- Further real-world comparative data against competing BTK inhibitors.
- BRUKINSA market share trends in frontline CLL treatment.
- Regulatory and commercial expansion opportunities across global markets.
- Future clinical studies evaluating BRUKINSA in additional hematologic malignancies and combination regimens.
The key takeaway is that BeOne continues to build an increasingly extensive body of clinical and real-world evidence supporting BRUKINSA’s role in first-line CLL, particularly among older patients who represent a large and growing segment of the treatment population.